Artificial Blood Vessels Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Artificial blood vessels, also known as vascular grafts, are medical devices used to replace or repair damaged or diseased natural blood vessels. They are essential in procedures such as coronary artery bypass grafting, peripheral artery disease treatment, and arteriovenous fistula creation for hemodialysis patients. The market comprises various product types, including vascular prostheses made from synthetic polymers like polyethylene terephthalate (Dacron) and expanded polytetrafluoroethylene (ePTFE), as well as biologic and hybrid grafts.

• •Market valued at approximately USD 2.19 billion in 2025 with a projected CAGR of roughly 7.1% through the early 2030s
• •Expected to reach or exceed USD 3.75 billion by 2034, driven by rising cardiovascular disease prevalence
• •Primary applications include coronary artery bypass grafting, peripheral artery disease treatment, and hemodialysis access

The increasing global burden of cardiovascular diseases, including coronary artery disease, peripheral artery disease, and end-stage renal disease requiring dialysis, is the primary catalyst for market expansion. An aging worldwide population and rising prevalence of diabetes and obesity further contribute to the growing patient pool requiring vascular interventions. Continuous innovation in biomaterials, including bioresorbable grafts, endothelialized surfaces, and tissue-engineered constructs, is expanding the range of treatable conditions and improving clinical outcomes.

• •Rising global prevalence of cardiovascular disease and end-stage renal disease driving demand for vascular grafts
• •Aging population and increasing incidence of diabetes and obesity expanding the addressable patient pool
• •Advancements in biomaterials and tissue engineering enabling improved graft biocompatibility and long-term performance

The market is segmented by product type, including synthetic vascular grafts (polyester, ePTFE), biologic grafts, and hybrid or bioresorbable solutions. Application segments cover coronary artery bypass grafting, peripheral artery disease, hemodialysis access, and others. North America holds the largest market share due to high healthcare expenditure, advanced medical infrastructure, and favorable reimbursement policies, while Europe follows closely. The Asia-Pacific region is expected to witness the fastest growth, propelled by improving healthcare access, rising medical tourism, and growing adoption of advanced surgical procedures in countries such as China, India, and Japan.

• •Key segments include synthetic grafts (polyester/Dacron and ePTFE), biologic grafts, and bioresorbable hybrid solutions
• •Application segments span coronary artery bypass, peripheral artery disease, hemodialysis access, and vascular trauma repair
• •Asia-Pacific is the fastest-growing regional market, while North America and Europe collectively account for the majority of global market share

What are the recent trends and outlook?

The market is trending toward the development of small-diameter vascular grafts that can effectively resist thrombosis, a longstanding clinical challenge, particularly for vessels smaller than 6 millimeters in diameter. 3D bioprinting and tissue-engineered vascular grafts using autologous cells represent emerging technologies with the potential to overcome limitations of current synthetic materials. Regulatory pathways for innovative vascular products are evolving, and as clinical evidence accumulates for next-generation grafts, adoption is expected to accelerate, supporting the market's projected trajectory toward USD 3.75 billion and beyond.

• •Development of small-diameter, anti-thrombogenic grafts is a major research and commercialization focus area
• •3D bioprinting and tissue-engineered vascular constructs are emerging as transformative technologies for the market
• •The market is on track to surpass USD 3.75 billion by 2034 as next-generation grafts gain regulatory approval and clinical adoption